Peptide Lab HQ Research Guide
CJC-1295 w/o DAC
A research-focused compound profile covering CJC-1295 without DAC identity, Modified GRF (1-29) research, GHRH receptor signaling, growth hormone axis context, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | CJC-1295 w/o DAC |
|---|---|
| Common Name | Modified GRF (1-29) |
| Compound Type | Synthetic growth hormone-releasing hormone analog |
| CAS Number | Commonly listed as 863288-34-0 for Modified GRF (1-29) / CJC-1295 without DAC |
| PubChem CID | 91976842 |
| Amino Acid Length | 29 amino acids |
| Amino Acid Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ |
| Research Category | GHRH analog, growth hormone axis, IGF-1 pathway, pituitary signaling, and endocrine research |
| Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Molecular Weight | Approximately 3367.9 g/mol |
| DAC Status | Without DAC; does not contain the drug affinity complex extension used in long-acting CJC-1295 DAC. |
| Appearance | White to off-white lyophilized powder |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
CJC-1295 w/o DAC is commonly discussed in controlled research models involving growth hormone-releasing hormone signaling, pituitary response, growth hormone pulse dynamics, IGF-1 pathway context, endocrine feedback loops, and combination research with ghrelin receptor agonists.
GHRH Receptor Research
CJC-1295 w/o DAC is commonly studied as a Modified GRF (1-29) analog interacting with growth hormone-releasing hormone receptor pathways.
Growth Hormone Axis Models
Used in research involving pituitary signaling, endogenous growth hormone release, pulse dynamics, and endocrine response documentation.
IGF-1 Pathway Context
Relevant to research involving downstream IGF-1 response, endocrine feedback, and growth hormone axis monitoring.
No-DAC Comparison Models
Commonly compared against long-acting DAC analogs in research discussions because the no-DAC form is structurally distinct and lacks the albumin-binding extension.
Combination Research Context
Frequently discussed in combination research models alongside ghrelin receptor agonists such as Ipamorelin due to complementary pituitary signaling pathways.
Endocrine Marker Research
Used in study contexts involving GH, IGF-1, glucose-related markers, sleep-cycle observations, and body-composition endpoint tracking.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on study model, peptide form, DAC status, purity, concentration, timing, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 2 mg CJC-1295 w/o DAC |
|---|---|
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 1 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 1 mg/mL, 1 unit equals 0.01 mg / 10 mcg CJC-1295 w/o DAC. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- Verify complete dissolution before recording the final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | CJC-1295 w/o DAC, commonly treated in public research references as Modified GRF (1-29) | CJC-1295 w/o DAC is commonly discussed as a non-DAC GHRH analog / modified GRF (1-29)-style peptide in growth-hormone-releasing hormone pathway research contexts. |
| DAC-Free Distinction | Non-DAC / no albumin-binding linker context | This reference is for the w/o DAC format. It should not be treated the same as DAC-containing CJC-1295, which is discussed separately in long-acting albumin-binding GHRH analog research. |
| GHRH Receptor Research | Growth hormone-releasing hormone receptor pathway context | Commonly discussed in GHRH receptor signaling, anterior pituitary response, GH pulse modeling, GH-marker tracking, and endocrine-axis research contexts. |
| GH / IGF-1 Axis Research | Model-dependent endocrine-marker tracking | CJC / modified GRF-style research discussions commonly include GH-marker response, IGF-1 marker tracking, somatotroph signaling, pituitary-axis response, and endocrine feedback documentation. |
| Peptide Stability Research Context | Modified GRF (1-29)-style substitutions | Public research references often distinguish modified GRF-style analogs from native GRF / Sermorelin-style fragments by discussing stability-oriented substitutions and shorter-acting, non-DAC research use. |
| Combination Research Context | Often discussed with GHRP / ghrelin-receptor pathway compounds | Public protocol-style references commonly pair CJC-1295 w/o DAC / Modified GRF-style references with GHRP-class compounds in GH-axis research models. These references are not clinical dosing standards. |
| Public Protocol-Style Reference | Microgram-to-milligram reference examples | Public protocol-style references commonly describe CJC-1295 w/o DAC in microgram-to-milligram examples depending on the research model and preparation format. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, preclinical references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 2 mg | 2.0 mL | 1 mg/mL |
| 5 mg | 2.0 mL | 2.5 mg/mL |
| 10 mg | 2.0 mL | 5 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 1 mg/mL | U-100 Unit Reference | Approx. References per 2 mg Vial |
|---|---|---|---|
| 25 mcg | 0.025 mL | 2.5 units | 80 |
| 50 mcg | 0.05 mL | 5 units | 40 |
| 0.1 mg / 100 mcg | 0.10 mL | 10 units | 20 |
| 0.25 mg / 250 mcg | 0.25 mL | 25 units | 8 |
| 0.5 mg / 500 mcg | 0.50 mL | 50 units | 4 |
| 1 mg / 1000 mcg | 1.00 mL | 100 units | 2 |
| 2 mg / 2000 mcg | 2.00 mL | 200 units | 1 |
| 5 mg / 5000 mcg | 5.00 mL | 500 units | 0.4 |
| 10 mg / 10000 mcg | 10.00 mL | 1000 units | 0.2 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Microgram Reference | Calculation reference only | 25 mcg reference amount | 2.5 units / 0.025 mL |
| Standard Microgram Reference | Calculation reference only | 50 mcg reference amount | 5 units / 0.05 mL |
| Low Milligram Conversion Example | Public protocol-style reference, not a clinical dosing standard | 0.1 mg reference amount | 10 units / 0.10 mL |
| Mid-Range Conversion Example | Public protocol-style reference, not a clinical dosing standard | 250 mcg reference amount | 25 units / 0.25 mL |
| Upper Conversion Example | Calculation reference only | 0.5 mg reference amount | 50 units / 0.50 mL |
| High Conversion Example | Calculation reference only | 1 mg reference amount | 100 units / 1.00 mL |
| 2 mg Preparation Reference | Preparation-level calculation reference | 2 mg reference amount | 200 units / 2.00 mL |
| 5 mg Preparation Reference | Preparation-level calculation reference | 5 mg reference amount | 500 units / 5.00 mL |
| 10 mg Preparation Reference | Preparation-level calculation reference | 10 mg reference amount | 1000 units / 10.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Receptor Observation Window | 24–72 hours | May be used for GHRH receptor signaling, somatotroph-response markers, GH-marker context, intracellular signaling, or peptide-response documentation depending on the model. |
| Acute Endocrine Observation Window | Single session to several days | Used for short-term GH-marker comparison, pituitary-axis response, IGF-1 marker observation, or early pathway tracking depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for early controlled observation involving GH-axis markers, IGF-1 marker tracking, endocrine-axis response, or peptide-stability comparison. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–8 weeks | Used when longer documentation is needed for endocrine-marker trends, GH / IGF-1 marker tracking, pituitary-axis response, or follow-up marker documentation. |
| Follow-Up / Washout | 1–4 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. CJC-1295 w/o DAC is commonly discussed in Modified GRF (1-29)-style, non-DAC GHRH analog, GHRH receptor, anterior pituitary, GH-axis, IGF-1 marker, somatotroph-response, endocrine-axis, and peptide-stability research contexts. The selector above updates calculations for 2 mg, 5 mg, and 10 mg vial references, each reconstituted with 2.0 mL bacteriostatic water. This page is for the w/o DAC reference format and should not be treated as the same preparation as DAC-containing CJC-1295. Published study references, preclinical research references, public protocol-style references, and wellness protocols are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
CJC-1295 w/o DAC is commonly discussed in research involving GHRH receptor signaling, pituitary response, endogenous growth hormone release, IGF-1 pathway context, and endocrine-marker tracking.
DAC Distinction
CJC-1295 w/o DAC should be distinguished from long-acting CJC-1295 DAC, which contains a drug affinity complex designed to alter pharmacokinetics and extend activity.
Safety Considerations
Research discussion should account for GH-axis activity, IGF-1 response, glucose-related markers, water retention, injection-site response, and endocrine feedback monitoring.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.